Skip to content

Endovenous Radiofrequency Ablation Closure System in the Treatment of Varicose Veins

Prospective, Multi-center, Randomized Controlled Study to Evaluate the Effectiveness and Safety of Endovenous Radiofrequency Ablation Closure System in the Treatment of Varicose Veins

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04671641
Enrollment
176
Registered
2020-12-17
Start date
2021-03-24
Completion date
2022-07-01
Last updated
2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose Veins

Brief summary

The goal of this clinical trial is to evaluate the effectiveness and safety of the endovenous radiofrequency ablation closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. for the treatment of varicose veins.

Detailed description

In this prospective, multi-center, randomized controlled study, 176 patients who were diagnosed with varicose veins and met the inclusion criteria without any exclusion criteria were randomly divided into the experimental group (Hongyuan Endovenous Radiofrequency Ablation Closure System)and control group (Medtronic's ClosureFast™ Radiofrequency Ablation System) at 1:1. The effectiveness of the product was evaluated by the vascular closure rate at 6 months after the operation, and the safety of the product was evaluated by the incidence of adverse events and serious adverse events within 6 months after the operation.

Interventions

DEVICEradiofrequency ablation

ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients

Sponsors

Suzhou Hengruihongyuan Medical Technology Co. LTD
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-80 years old, no gender limit. 2. Great saphenous varicose, CEAP grade C2-C6. 3. The diameter of the diseased vein is ≥2mm, ≤15mm. 4. Expected survival period ≥ 6 months. 5. The informed consent form can be signed by the patient or the legal representative.

Exclusion criteria

1. Are pregnant or breastfeeding. 2. Participating in clinical trials of other devices or drugs. 3. Deep vein thrombosis in the affected limb. 4. Uncorrectable coagulation dysfunction and obvious abnormal blood picture, with obvious bleeding tendency (platelets≤30x109/L). 5. Acute thrombosis in the main saphenous vein of the affected limb. 6. The investigator judged that it is not suitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Vascular closure rate at 6 months after the operation6 monthsCalculation method: completely closed patients / total cases of subjects in the same group x 100%. Definition of complete closure: Complete closure refers to ultrasound follow-up at 6 months after surgery that shows no blood flow in varicose veins.

Secondary

MeasureTime frameDescription
CEAP6 monthsThe CEAP is an elaborate scoring system for varicose veins and other disorders from venous insufficiency. It has been developed to determine the severity of the condition for diagnosis and treatment point of view. CEAP stands for: Clinical Etiopathological Anatomical Pathophysiological
Technical success rate6 monthsThe device is delivered in place and withdrawn smoothly, and the target diseased blood vessel is immediately examined by ultrasound without blood flow.
Evaluation of the use of devices6 monthsFor endovenous radiofrequency closure catheter: evaluation on the degree of device flexibility, crossability, accuracy, usability (subjective evaluation scale: excellent, good and poor) For endovenous radiofrequency closure generator: evaluation on applicability,accuracy of identifying catheter version, stability in the procedure(subjective evaluation: yes or no)
VCSS6 monthsChanges from baseline in venous clinical severity score (VCSS) (0-30, higher scores mean a worse outcome) in outpatient services. the VCSS was derived by the American Venous Forum from the CEAP classification and provides means by which clinical outcomes in venous disease can be monitored in time.Compared to the CEAP, VCSS is said to be more responsive to changes in disease severity, thus making it great for progressive rankings. It proved good inter and intra observer reproducibility and is often cited in quality of life assessments

Other

MeasureTime frame
Rate of serious adverse events within 6 months after surgery6 months
Rate of adverse events within 6 months after surgery6 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026